Delcath Systems (DCTH) said late Tuesday it published two investigator-initiated trials-in-progress abstracts on May 21.
The company said these abstracts will be presented at the 2026 American Society of Clinical Oncology annual meeting in Chicago, highlighting ongoing clinical investigations of Delcath's percutaneous hepatic perfusion with melphalan using the HEPZATO KIT (TM) Hepatic Delivery System in metastatic melanoma involving the liver.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.